Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

Purpose: We used high-resolution oligonucleotide comparative genomic hybridization (CGH) arrays and matching gene expression array data to identify dysregulated genes and to classify breast cancers according to gene copy number anomalies. Experimental Design: DNA was extracted from 106 pretreatment fine needle aspirations of stage II-III breast cancers that received preoperative chemotherapy. CGH was done using Agilent Human 4 × 44K arrays. Gene expression data generated with Affymetrix U133A gene chips was also available on 103 patients. All P values were adjusted for multiple comparisons. Results: The average number of copy number abnormalities in individual tumors was 76 (range 1-318). Eleven and 37 distinct minimal common regions were gained or lost in >20% of samples, respectively. Several potential therapeutic targets were identified, including FGFR1 that showed high-level amplification in 10% of cases. Close correlation between DNA copy number and mRNA expression levels was detected. Nonnegative matrix factorization (NMF) clustering of DNA copy number aberrations revealed three distinct molecular classes in this data set. NMF class I was characterized by a high rate of triple-negative cancers (64%) and gains of 6p21. VEGFA, E2F3, and NOTCH4 were also gained in 29% to 34% of triple-negative tumors. A gain of ERBB2 gene was observed in 52% of NMF class II and class III was characterized by a high rate of estrogen receptor–positive tumors (73%) and a low rate of pathologic complete response to preoperative chemotherapy (3%). Conclusion: The present study identified dysregulated genes that could classify breast cancer and may represent novel therapeutic targets for molecular subsets of cancers.

[1]  G. Hortobagyi,et al.  Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers , 2008 .

[2]  Lajos Pusztai,et al.  Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer , 2007, Clinical Cancer Research.

[3]  J. Fridlyand,et al.  Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. , 2007, Cancer research.

[4]  Judith Abrams,et al.  Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. , 2006, Cancer research.

[5]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[6]  Alan Mackay,et al.  FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.

[7]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[8]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Christian J Stoeckert,et al.  STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. , 2006, Genome research.

[10]  Jeroen Beliën,et al.  ACE-it: a tool for genome-wide integration of gene dosage and RNA expression data , 2006, Bioinform..

[11]  P. Nederlof,et al.  Array-CGH and breast cancer , 2006, Breast Cancer Research.

[12]  Ajay N. Jain,et al.  Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.

[13]  C. Rouveirol,et al.  Computation of recurrent minimal genomic alterations from array-CGH data , 2006, Bioinform..

[14]  Meritxell Bellet,et al.  The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. , 2006, Cancer genetics and cytogenetics.

[15]  B. Ylstra,et al.  BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH) , 2006, Nucleic acids research.

[16]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[17]  Zohar Yakhini,et al.  Joint Analysis of DNA Copy Numbers and Gene Expression Levels , 2004, WABI.

[18]  David E. Gloriam,et al.  The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. , 2004, Genomics.

[19]  D. Ginsberg.  E2F3-a novel repressor of the ARF/p53 pathway. , 2004, Developmental cell.

[20]  G. Meijer,et al.  Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma , 2004, Modern Pathology.

[21]  Pablo Tamayo,et al.  Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Saydam,et al.  DNA copy number changes detected by comparative genomic hybridization and their association with clinicopathologic parameters in breast tumors. , 2003, Cancer genetics and cytogenetics.

[23]  J. Stec,et al.  Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma , 2003, Cancer.

[24]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Prendergast,et al.  RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[27]  S. Nass,et al.  Defining a role for c-Myc in breast tumorigenesis , 1997, Breast Cancer Research and Treatment.

[28]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[29]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .

[30]  Bongsoo Park,et al.  BMC Genomics , 2007 .

[31]  J. Fridlyand,et al.  Deletion of Chromosome 11 q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer , 2007 .

[32]  Ian M. Wilson,et al.  Array CGH technologies and their applications to cancer genomes , 2005, Chromosome Research.

[33]  B. Dörken,et al.  Apoptosis: implications of basic research for clinical oncology. , 2001, The Lancet. Oncology.

[34]  P. Sneath,et al.  Numerical Taxonomy , 1962, Nature.